Light chain disease

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

MIDD; Monoclonal immunoglobulin deposition disease

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Kidney disease associated with a non-fibrillary deposition of monoclonal immunoglobulin fragments (light chains).

Occurrence/EpidemiologyThis section has been translated automatically.

2/3 of light chain diseases are caused by multiple myeloma.

EtiopathogenesisThis section has been translated automatically.

In multiple myeloma, the light chains accumulate in the lysosomes and cannot be degraded by proteases. The resulting atrophy of the proximal tubule cells is one of the decisive factors for renal insufficiency.

ManifestationThis section has been translated automatically.

Mean age of onset of light chain disease: 55 years

Clinical featuresThis section has been translated automatically.

The light chain disease can show one or more of the following symptoms:

  • renal insufficiency (90%)
  • Rapid loss of renal function (70%)
  • proteinuria (84%)
  • Nephrotic syndrome(40%)
  • Microhaematuria (30%)
  • Heart and liver involvement (30%)

Complication(s)This section has been translated automatically.

The light chain disease can lead to severe renal failure.

LiteratureThis section has been translated automatically.

  1. Hirashio S et al, (2018) A case of immunotactoid glomerulopathy with false-negative IgG staining. BMC Nephrol 19:143.
  2. Karasawa K et al, (2018) Successful treatment with rituximab of immunotactoid glomerulopathy exhibiting nephrotic syndrome. Clin Nephrol 90:222-226.
  3. Motwani SS et al (2016) Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol 11:2260-2272.
  4. Nasr SH et al (2017) DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep 3:56-64.
  5. Sehgal R et al (2017) Fibrillary Glomerulonephritis in Primary Sjogren's Syndrome: A Rare Cause of Renal Failure. Clin Med Res 15(3-4):100-105.

Authors

Last updated on: 29.10.2020